Inhibrx公布INBRX-106一线治疗HNSCC的2期中期数据；初步结果显示其较PD-1单药疗法具有潜在共刺激优势

美股速递

May 11

Inhibrx Biosciences (INBX) 公布了其候选药物INBRX-106在一线治疗头颈部鳞状细胞癌（HNSCC）患者中的2期临床试验中期数据。初步分析表明，INBRX-106可能展现出超越现有PD-1单药疗法的共刺激活性优势，为这一治疗领域带来了新的希望。

头颈部鳞状细胞癌的治疗长期面临挑战，尽管免疫检查点抑制剂如PD-1单抗已取得进展，但疗效提升空间依然显著。INBRX-106作为一种设计新颖的双特异性分子，旨在同时靶向特定的免疫通路，可能通过增强T细胞的激活与功能来对抗肿瘤。

此次公布的中期结果，虽然仍属早期数据，但揭示了INBRX-106在初步疗效信号和耐受性方面的积极迹象。研究旨在评估其与标准疗法相比的潜力，特别是观察其是否能提供PD-1单药疗法所不具备的协同免疫激活效应——即所谓的“共刺激效益”。这为开发更有效的联合疗法或单药方案提供了科学依据。

公司表示，这些数据支持继续推进INBRX-106的临床开发计划。后续研究将关注更长期的疗效终点、更大患者群体的数据以及更深入的作用机制分析。投资者和行业观察人士正密切关注该药物的进展，因其可能影响未来HNSCC乃至其他实体瘤的治疗格局。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1144007889"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144007889\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144007889?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-05-11 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144007889","market":"us","top_or_hot":-1,"title":"Inhibrx公布INBRX-106一线治疗HNSCC的2期中期数据；初步结果显示其较PD-1单药疗法具有潜在共刺激优势","media":"美股速递","content":"<p>Inhibrx Biosciences (INBX) 公布了其候选药物INBRX-106在一线治疗头颈部鳞状细胞癌（HNSCC）患者中的2期临床试验中期数据。初步分析表明，INBRX-106可能展现出超越现有PD-1单药疗法的共刺激活性优势，为这一治疗领域带来了新的希望。</p>\n<p>头颈部鳞状细胞癌的治疗长期面临挑战，尽管免疫检查点抑制剂如PD-1单抗已取得进展，但疗效提升空间依然显著。INBRX-106作为一种设计新颖的双特异性分子，旨在同时靶向特定的免疫通路，可能通过增强T细胞的激活与功能来对抗肿瘤。</p>\n<p>此次公布的中期结果，虽然仍属早期数据，但揭示了INBRX-106在初步疗效信号和耐受性方面的积极迹象。研究旨在评估其与标准疗法相比的潜力，特别是观察其是否能提供PD-1单药疗法所不具备的协同免疫激活效应——即所谓的“共刺激效益”。这为开发更有效的联合疗法或单药方案提供了科学依据。</p>\n<p>公司表示，这些数据支持继续推进INBRX-106的临床开发计划。后续研究将关注更长期的疗效终点、更大患者群体的数据以及更深入的作用机制分析。投资者和行业观察人士正密切关注该药物的进展，因其可能影响未来HNSCC乃至其他实体瘤的治疗格局。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx公布INBRX-106一线治疗HNSCC的2期中期数据；初步结果显示其较PD-1单药疗法具有潜在共刺激优势</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx公布INBRX-106一线治疗HNSCC的2期中期数据；初步结果显示其较PD-1单药疗法具有潜在共刺激优势\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-05-11 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Inhibrx Biosciences (INBX) 公布了其候选药物INBRX-106在一线治疗头颈部鳞状细胞癌（HNSCC）患者中的2期临床试验中期数据。初步分析表明，INBRX-106可能展现出超越现有PD-1单药疗法的共刺激活性优势，为这一治疗领域带来了新的希望。</p>\n<p>头颈部鳞状细胞癌的治疗长期面临挑战，尽管免疫检查点抑制剂如PD-1单抗已取得进展，但疗效提升空间依然显著。INBRX-106作为一种设计新颖的双特异性分子，旨在同时靶向特定的免疫通路，可能通过增强T细胞的激活与功能来对抗肿瘤。</p>\n<p>此次公布的中期结果，虽然仍属早期数据，但揭示了INBRX-106在初步疗效信号和耐受性方面的积极迹象。研究旨在评估其与标准疗法相比的潜力，特别是观察其是否能提供PD-1单药疗法所不具备的协同免疫激活效应——即所谓的“共刺激效益”。这为开发更有效的联合疗法或单药方案提供了科学依据。</p>\n<p>公司表示，这些数据支持继续推进INBRX-106的临床开发计划。后续研究将关注更长期的疗效终点、更大患者群体的数据以及更深入的作用机制分析。投资者和行业观察人士正密切关注该药物的进展，因其可能影响未来HNSCC乃至其他实体瘤的治疗格局。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1144007889","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144007889","pubTimestamp":1778500907,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Inhibrx Biosciences  公布了其候选药物INBRX-106在一线治疗头颈部鳞状细胞癌患者中的2期临床试验中期数据。初步分析表明，INBRX-106可能展现出超越现有PD-1单药疗法的共刺激活性优势，为这一治疗领域带来了新的希望。头颈部鳞状细胞癌的治疗长期面临挑战，尽管免疫检查点抑制剂如PD-1单抗已取得进展，但疗效提升空间依然显著。公司表示，这些数据支持继续推进INBRX-106的临床开发计划。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","INBX":"Inhibrx Biosciences"},"translate_title":"Inhibrx announces phase 2 interim data of INBRX-106 first-line treatment for HNSCC; Preliminary results show potential costimulatory advantages over PD-1 monotherapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":1},"content_text":"Inhibrx Biosciences (INBX) 公布了其候选药物INBRX-106在一线治疗头颈部鳞状细胞癌（HNSCC）患者中的2期临床试验中期数据。初步分析表明，INBRX-106可能展现出超越现有PD-1单药疗法的共刺激活性优势，为这一治疗领域带来了新的希望。\n头颈部鳞状细胞癌的治疗长期面临挑战，尽管免疫检查点抑制剂如PD-1单抗已取得进展，但疗效提升空间依然显著。INBRX-106作为一种设计新颖的双特异性分子，旨在同时靶向特定的免疫通路，可能通过增强T细胞的激活与功能来对抗肿瘤。\n此次公布的中期结果，虽然仍属早期数据，但揭示了INBRX-106在初步疗效信号和耐受性方面的积极迹象。研究旨在评估其与标准疗法相比的潜力，特别是观察其是否能提供PD-1单药疗法所不具备的协同免疫激活效应——即所谓的“共刺激效益”。这为开发更有效的联合疗法或单药方案提供了科学依据。\n公司表示，这些数据支持继续推进INBRX-106的临床开发计划。后续研究将关注更长期的疗效终点、更大患者群体的数据以及更深入的作用机制分析。投资者和行业观察人士正密切关注该药物的进展，因其可能影响未来HNSCC乃至其他实体瘤的治疗格局。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}